We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.1%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.9B
AUM Growth
+$737M
Cap. Flow
-$219M
Cap. Flow %
-1.29%
Top 10 Hldgs %
56.42%
Holding
122
New
26
Increased
36
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$353M
2
EQIX icon
Equinix
EQIX
+$266M
3
BKNG icon
Booking.com
BKNG
+$252M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$203M
5
AABA
Altaba Inc
AABA
+$162M

Top Sells

Rank Stock Value
1
KDP icon
Keurig Dr Pepper
KDP
+$596M
2
XL
XL Group Ltd.
XL
+$407M
3
LOGM
LogMein, Inc.
LOGM
+$214M
4
GILD icon
Gilead Sciences
GILD
+$207M
5
IQV icon
IQVIA
IQV
+$126M

Sector Composition

Rank Sector Weight
1 Healthcare 24.46%
2 Technology 17.58%
3 Communication Services 13.12%
4 Financials 12.19%
5 Industrials 9.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
51
CRISPR Therapeutics
CRSP
$5.75B
$45.2M 0.27%
1,018,594
+157,894
+18% +$8.27M
MRTX
52
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$41.2M 0.24%
875,000
+131,500
+18% +$7.32M
GRFS
53
Grifois
GRFS
$5.44B
$38.3M 0.23%
1,790,000
+1,238,696
+225% +$26.1M
RC
54
Ready Capital
RC
$311M
$36.7M 0.22%
2,203,239
-5,000
-0.2% -$83.6K
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
$36.4M 0.21%
2,043,149
-2,043,151
-50% -$46.2M
SRPT icon
56
Sarepta Therapeutics
SRPT
$1.98B
$31.5M 0.19%
+195,000
New +$26.7M
IDTI
57
DELISTED
Integrated Device Technology I
IDTI
$30.1M 0.18%
+640,000
New +$24.7M
SVRA icon
58
Savara
SVRA
$1.15B
$27M 0.16%
2,418,009
+193,009
+9% +$2.22M
BUD icon
59
AB InBev
BUD
$155B
$25.7M 0.15%
293,109
-65,424
-18% -$6.38M
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$31.6B
$24.2M 0.14%
276,551
-138,449
-33% -$13.9M
TECX
61
Tectonic Therapeutic
TECX
$736M
$24.1M 0.14%
38,750
+9,300
+32% +$4.12M
PTGX icon
62
Protagonist Therapeutics
PTGX
$9.99B
$23.1M 0.14%
2,243,202
+1,332,973
+146% +$11.5M
PGNX
63
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$22.7M 0.13%
3,612,820
+961,720
+36% +$7.39M
ZYME icon
64
Zymeworks
ZYME
$2.05B
$21M 0.12%
1,335,000
+580,000
+77% +$8.3M
PTCT icon
65
PTC Therapeutics
PTCT
$5.83B
$19.7M 0.12%
+420,000
New +$17.4M
APTX
66
DELISTED
Aptinyx Inc. Common Stock
APTX
$19.4M 0.11%
670,000
+73,200
+12% +$1.78M
EXEL icon
67
Exelixis
EXEL
$13.4B
$19.1M 0.11%
+1,080,000
New +$21.1M
LRMR icon
68
Larimar Therapeutics
LRMR
$434M
$19M 0.11%
135,417
+29,872
+28% +$3.63M
PBYI icon
69
Puma Biotechnology
PBYI
$477M
$18.8M 0.11%
+410,000
New +$19.8M
VYGR icon
70
Voyager Therapeutics
VYGR
$209M
$17.2M 0.1%
909,158
+141,001
+18% +$2.71M
CDXS icon
71
Codexis
CDXS
$183M
$17.1M 0.1%
1,000,000
-125,000
-11% -$2.02M
BPY
72
DELISTED
Brookfield Property Partners L.P. Limited Partnership Units
BPY
$16.6M 0.1%
+794,382
New +$15.9M
SHPG
73
DELISTED
Shire pic
SHPG
$15.8M 0.09%
87,000
+17,453
+25% +$3.02M
NTLA icon
74
Intellia Therapeutics
NTLA
$1.8B
$15.7M 0.09%
550,000
-290,000
-35% -$8.44M
ZEAL
75
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$14.9M 0.09%
900,000
– –
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2018 Portfolio in Review

As of Q3 2018, Thomas Steyer held 122 positions worth $16.9B, up 4.6% from $16.2B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Thomas Steyer's Q3 2018 filing shows 26 new, 36 increased, 29 reduced and 20 closed positions. Its largest new stake was Equinix: 608,600 shares worth $263M. The largest sale was Keurig Dr Pepper, an estimated $596M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 21% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q3 2018 buy was Equinix: 608,600 shares worth $263M.
  • Thomas Steyer added most to Express Scripts Holding Company in Q3 2018, an estimated $353M increase.
  • Thomas Steyer's biggest Q3 2018 reduction was IQVIA, cutting an estimated $126M.
  • Thomas Steyer fully exited Keurig Dr Pepper in Q3 2018, selling an estimated $596M.
  • Thomas Steyer's ten largest holdings make up 56% of its $16.9B portfolio in Q3 2018.
  • Thomas Steyer opened 26 new positions and closed 20 in Q3 2018.
  • Thomas Steyer's portfolio value rose 4.6% quarter-over-quarter to $16.9B.

Based on Farallon Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.